Safety of baclofen versus tizanidine for older adults with musculoskeletal pain
- PMID: 36989193
- DOI: 10.1111/jgs.18349
Safety of baclofen versus tizanidine for older adults with musculoskeletal pain
Abstract
Background: Baclofen and tizanidine are both muscle relaxants that carry the risk for neuropsychiatric events in older adults but there is a lack of data directly comparing their safety. This study aimed to investigate the relative risk between these two medications in causing injury and delirium in older adults.
Methods: This was a retrospective cohort study that was completed in an integrated healthcare system in the United States and included patients aged 65 years or older who started baclofen or tizanidine for the treatment of musculoskeletal pain from January 2016 through December 2018. Outcomes included new incidence of injury (concussion, contusion, dislocation, fall, fracture, or other injuries) and delirium. The cohort was followed from the initiation of therapy until the first occurrence of any of the following events: end of the index drug exposure, end of health plan membership, death, or the study end date of December 31st, 2019. Descriptive statistics were used to compare baseline patient characteristics between baclofen and tizanidine treatment groups. Cox proportional hazards model was used to calculate adjusted hazard ratios (HRs) with 95% confidence intervals.
Results: The final study cohort included 12,101 and 6,027 older adults in the baclofen and tizanidine group respectively (mean age 72.2 ± 6.2 years old, 59% female). Older adults newly started on baclofen had a greater risk of injury (HR = 1.54, 95% CI = 1.21-1.96, P = < 0.001) and delirium (HR = 3.33, 95% CI = 2.11-5.26, p = <0.001) compared to those started on tizanidine.
Conclusion: The results of this study suggest that baclofen is associated with higher incidences of injury and delirium compared to tizanidine when used for the treatment of musculoskeletal pain. Future studies should investigate if these risks are dose-related and include a comparison group not exposed to either drug.
Keywords: baclofen; delirium; injury; safety; tizanidine.
© 2023 The American Geriatrics Society.
Similar articles
-
Baclofen and the risk of fall and fracture in older adults: A real-world cohort study.J Am Geriatr Soc. 2024 Jan;72(1):91-101. doi: 10.1111/jgs.18665. Epub 2023 Nov 7. J Am Geriatr Soc. 2024. PMID: 37933734
-
Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.J Pain Symptom Manage. 2004 Aug;28(2):140-75. doi: 10.1016/j.jpainsymman.2004.05.002. J Pain Symptom Manage. 2004. PMID: 15276195 Review.
-
Baclofen and Tizanidine Adverse Effects Observed Among Community-Dwelling Adults Above the Age of 50 Years: A Systematic Review.Ann Pharmacother. 2024 May;58(5):523-532. doi: 10.1177/10600280231193080. Epub 2023 Aug 17. Ann Pharmacother. 2024. PMID: 37589096 Review.
-
Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.Curr Med Res Opin. 1988;10(10):699-708. doi: 10.1185/03007998809111121. Curr Med Res Opin. 1988. PMID: 3286128 Clinical Trial.
-
A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.Curr Med Res Opin. 1981;7(6):374-83. Curr Med Res Opin. 1981. PMID: 7016449 Clinical Trial.
Cited by
-
Tizanidine: Advances in Pharmacology & Therapeutics and Drug Formulations.J Pain Res. 2024 Mar 21;17:1257-1271. doi: 10.2147/JPR.S461032. eCollection 2024. J Pain Res. 2024. PMID: 38529017 Free PMC article. Review.
-
Baclofen and the risk of fall and fracture in older adults: A real-world cohort study.J Am Geriatr Soc. 2024 Jan;72(1):91-101. doi: 10.1111/jgs.18665. Epub 2023 Nov 7. J Am Geriatr Soc. 2024. PMID: 37933734
References
REFERENCES
-
- Welsh TP, Yang AE, Makris UE. Musculoskeletal pain in older adults: a clinical review. Med Clin North Am. 2020;104(5):855-872. doi:10.1016/j.mcna.2020.05.002
-
- Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001-1006. doi:10.15585/mmwr.mm6736a2. Published 2018 Sep 14.
-
- Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J. Effective treatment options for musculoskeletal pain in primary care: a systematic overview of current evidence. PLoS One. 2017;12(6):e0178621. doi:10.1371/journal.pone.0178621 Published 2017 Jun 22.
-
- Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140-175. doi:10.1016/j.jpainsymman.2004.05.002 PMID: 15276195.
-
- Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998;15(4):241-51. PMID: 10186943-251.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
